The Longitudinal Evaluation of Ovarian Aging and Cardiovascular Risk

NCT ID: NCT03825120

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Total Enrollment: 865 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2018-08-15
• Study Completion Date: 2025-12-02

Brief Summary

Despite significant improvements in prevention and treatment of cardiovascular disease (CVD), the growing aging population suggests CVD will continue to pose a significant public health burden. Women are a special group where microvascular disease is more common and traditional risk factors may not fully identify risk. Women's reproductive history (e.g. menarcheal age, menstrual cycles, infertility, pregnancy, menopause) may pose unique risk and suggests an opportunity for new approaches. The investigators propose a women-centered approach for early identification of women at risk that investigates the unique loss of reproductive function at an age long before other vital systems fail. Despite its importance, little is known about the determinants or correlates of ovarian aging, or the health implications, especially in diverse communities. Only recently have reliable biomarkers of the remaining oocyte pool been available for use in normally cycling women. This availability gives us a unique opportunity to characterize the association between "ovarian age" (cross-sectional) and the rate of "ovarian aging" or oocyte decline over time (longitudinal) and the health implications of accelerated oocyte loss. The investigators hypothesize ovarian age/aging provides a window onto the general health of women. The investigators suggest it is not the progressive deficiency of estrogen with menopause that increases risk, but common underlying cellular aging mechanisms first evident in young populations as lower ovarian reserve (follicle number) due to the unique sensitivity of the ovary.

Studies of cellular aging focused on mitochondrial dysfunction, oxidative stress, inflammation, and telomere length have identified correlations with CVD risk. Improved understanding of the mechanisms of cellular aging suggests telomere shortening and dysfunction may drive mitochondrial dysfunction and potentially the parallel between cellular aging and CVD. The oocyte is particularly sensitive to mitochondrial dysfunction, having 10 times the number of mitochondria as any somatic cell. Additionally, mitochondrial dysfunction and telomere shortening have been associated with ovarian aging. This begs the question of whether, given the susceptibility of the ovary to mitochondrial dysfunction, accelerated ovarian aging may be a harbinger of subsequent CVD risk. To address this critical question, the investigators propose to leverage the largest and most ethnically diverse population of normal reproductive-aged women, with detailed measures of ovarian age, and to deploy peripheral endothelial function testing, a non-invasive sensitive marker of early CVD risk. Ovarian aging is thought to be largely genetically determined, but the impact of race/ethnicity has not been fully explored. Evaluating the impact of ethnicity on ovarian aging, and combining this information with the impact of modifiable behavioral risk factors, may help clarify CVD risk in young, ethnically-diverse, reproductive-age women. The investigators believe improving our understanding of factors that affect the rate of oocyte/follicle loss and the relationship with CVD risk factors will promote a novel method to identify women at earlier and/or increased cardiac risk.

Detailed Description

The investigators propose to carry out three Specific Aims:

1. Determine whether markers of ovarian age/aging are associated with increased CVD risk.

Specifically, the investigators propose to assess whether:

1. Ovarian age predicts CVD risk (measured by peripheral endothelial function testing) independent of chronological age.

2. The rate of ovarian aging is independently associated with increased CVD risk after adjustment for ovarian and chronological age.

2. Determine whether ovarian aging may moderate or mediate established associations between race/ethnicity and CVD risk and socio/emotional health and CVD risk. Specifically, the investigators propose to:

1. Examine whether observed race/ethnic disparities in CVD risk (measured by peripheral endothelial function testing) may vary by (moderation model) or be partially attributable to (mediation model) ovarian aging.

2. Examine whether effects of socio/emotional health (as indexed by separate composites of psychosocial functioning and socioeconomic status) on CVD risk may vary by (moderation model) or be partially attributable to (mediation model) ovarian aging.

3. Determine if similar mechanisms of cellular aging underlie both ovarian aging and CVD risk. Temporal appearance of indices of cellular aging, ovarian aging and CVD risk would support our primary hypothesis. Specifically, we propose to determine whether telomere and mtDNA in peripheral leukocytes, oxidative stress (plasma F2-isoprostanes), and indices of inflammation (C-reactive protein, interleukin-6, and soluble intercellular adhesion molecule-1) correlate with both ovarian aging and CVD risk, and the temporal pattern of appearance.

Conditions

Infertility; Cardiovascular Risk Factor

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Women from original OVA cohort

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Enrollment into the original OVA cohort (NCT00501800)

Exclusion Criteria

• Not a member of the original OVA cohort

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Aging (NIA)

NIH

Sponsor Role: collaborator

University of California, San Francisco

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marcelle I Cedars, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

University of California, San Francisco

San Francisco, California, United States

Countries

United States

Other Identifiers

1R01AG053332-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01AG053332

Identifier Type: NIH

Identifier Source: org_study_id

View Link